Cardiol Therapeutics (CRDL) Registration Filing summary

Company overview and business model

• Clinical-stage life sciences company focused on anti-inflammatory and anti-fibrotic therapies for heart diseases, with lead candidate CardiolRx (cannabidiol) in clinical development for recurrent pericarditis and acute myocarditis.

• CardiolRx targets inflammasome pathway, implicated in inflammation and fibrosis in myocarditis, pericarditis, and heart failure.

• Received FDA Orphan Drug Designation for pericarditis; planning to pursue similar designation for acute myocarditis.

• Developing a novel subcutaneous cannabidiol formulation for heart failure, addressing a market with over $30 billion in annual US healthcare costs.

Financial performance and metrics

• As of March 31, 2024: cash and cash equivalents of $28.6M, share capital of $151.1M, contributed surplus of $17.2M, and a deficit of $151.8M, with total capitalization at $20.1M.

• Negative operating cash flow in recent years; ongoing need to fund negative cash flow from operations.

Use of proceeds and capital allocation

• Net proceeds will be used for business objectives, general corporate purposes, working capital, debt repayment, capital programs, and potential acquisitions.

• Key milestones: complete Phase II MAVERIC-Pilot study (H2 2024, $500K), Phase III pericarditis study (TBD, $20M), complete Phase II ARCHER trial (H1 2025, $5M), initiate Phase III ARCHER trial (TBD, $10M), and advance CRD-38 program.

• Estimated $2–2.5M per quarter in general and administrative costs, with sufficient resources for near-term milestones.